92 related articles for article (PubMed ID: 24854682)
1. High grade osteosarcoma. Clinico-pathological aspects and molecular prognostic factors.
Tirabosco R
Clin Biochem; 2014 Jun; 47(9):735-6. PubMed ID: 24854682
[No Abstract] [Full Text] [Related]
2. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma.
Smida J; Baumhoer D; Rosemann M; Walch A; Bielack S; Poremba C; Remberger K; Korsching E; Scheurlen W; Dierkes C; Burdach S; Jundt G; Atkinson MJ; Nathrath M
Clin Cancer Res; 2010 Aug; 16(16):4256-67. PubMed ID: 20610556
[TBL] [Abstract][Full Text] [Related]
3. SAS is amplified predominantly in surface osteosarcoma.
Noble-Topham SE; Burrow SR; Eppert K; Kandel RA; Meltzer PS; Bell RS; Andrulis IL
J Orthop Res; 1996 Sep; 14(5):700-5. PubMed ID: 8893761
[TBL] [Abstract][Full Text] [Related]
4. MIR-10b IS inversely correlated with higher tumor grade in osteosarcoma.
Roberto GM; Engel EE; Tone LG; Brassesco MS
Clin Chim Acta; 2019 Mar; 490():164-166. PubMed ID: 29180037
[No Abstract] [Full Text] [Related]
5. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.
Baumhoer D; Smida J; Specht K; Bink K; Quintanilla-Martinez L; Rosemann M; Siggelkow H; Nathrath WB; Atkinson MJ; Bielack S; Jundt G; Nathrath M
Hum Pathol; 2011 Jun; 42(6):859-66. PubMed ID: 21292304
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of HER2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma.
Lee WI; Bacchni P; Bertoni F; Maeng YH; Park YK
Oncol Rep; 2004 Jul; 12(1):125-8. PubMed ID: 15201972
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics of osteosarcomas and cell aneuploidy in children and adolescents -- retrospective studies].
Rytwinski K; Rychlowska M; Wnuk A; Klepacka T; Michalak E
Med Wieku Rozwoj; 2001; 5(3):273-81. PubMed ID: 12004160
[TBL] [Abstract][Full Text] [Related]
9. Comparative genomic hybridization of low-grade central osteosarcoma.
Tarkkanen M; Böhling T; Gamberi G; Ragazzini P; Benassi MS; Kivioja A; Kallio P; Elomaa I; Picci P; Knuutila S
Mod Pathol; 1998 May; 11(5):421-6. PubMed ID: 9619593
[TBL] [Abstract][Full Text] [Related]
10. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.
Fernanda Amary M; Ye H; Berisha F; Khatri B; Forbes G; Lehovsky K; Frezza AM; Behjati S; Tarpey P; Pillay N; Campbell PJ; Tirabosco R; Presneau N; Strauss SJ; Flanagan AM
Cancer Med; 2014 Aug; 3(4):980-7. PubMed ID: 24861215
[TBL] [Abstract][Full Text] [Related]
11. NPRL2 is an independent prognostic factor of osteosarcoma.
Gao Y; Wang J; Fan G
Cancer Biomark; 2012-2013; 12(1):31-6. PubMed ID: 23321467
[TBL] [Abstract][Full Text] [Related]
12. Osteosarcoma: basic science and clinical implications.
Hayden JB; Hoang BH
Orthop Clin North Am; 2006 Jan; 37(1):1-7. PubMed ID: 16311106
[TBL] [Abstract][Full Text] [Related]
13. Overexpression through amplification of genes in chromosome region 17p11.2 approximately p12 in high-grade osteosarcoma.
van Dartel M; Redeker S; Bras J; Kool M; Hulsebos TJ
Cancer Genet Cytogenet; 2004 Jul; 152(1):8-14. PubMed ID: 15193436
[TBL] [Abstract][Full Text] [Related]
14. [Aneuploidy and histopathological classification, according to the Musculoskeletal Tumour Society and WHO, of osteosarcoma in children and adolescents].
Rytwinski K; Klepacka T; Wnuk A; Michalak E
Med Wieku Rozwoj; 2000; 4(4):373-82. PubMed ID: 11228595
[TBL] [Abstract][Full Text] [Related]
15. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
16. Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion.
Saba KH; Cornmark L; Rissler M; Fioretos T; Åström K; Haglund F; Rosenberg AE; Brosjö O; Nord KH
Genes Chromosomes Cancer; 2019 Oct; 58(10):731-736. PubMed ID: 31066955
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.
Buddingh EP; Kuijjer ML; Duim RA; Bürger H; Agelopoulos K; Myklebost O; Serra M; Mertens F; Hogendoorn PC; Lankester AC; Cleton-Jansen AM
Clin Cancer Res; 2011 Apr; 17(8):2110-9. PubMed ID: 21372215
[TBL] [Abstract][Full Text] [Related]
18. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma.
Yang J; Cogdell D; Yang D; Hu L; Li H; Zheng H; Du X; Pang Y; Trent J; Chen K; Zhang W
Cancer Lett; 2010 May; 291(1):31-8. PubMed ID: 19896763
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma.
Shimizu T; Ishikawa T; Iwai S; Ueki A; Sugihara E; Onishi N; Kuninaka S; Miyamoto T; Toyama Y; Ijiri H; Mori H; Matsuzaki Y; Yaguchi T; Nishio H; Kawakami Y; Ikeda Y; Saya H
Mol Cancer Res; 2012 Mar; 10(3):454-68. PubMed ID: 22228819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
